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but only for well-selected patients (young,
without history of malignancy or smoking,
with a nodule radiologic pattern of benig-
nity or nodules with small dimension). We
think that the clinician in a well-determined
situation does have the option of a short
watchful period.4 But for us the watchful
period doesn’t last 90 days without any
radiologic control; in fact our waiting pe-
riod is shorter than 90 days, and every 20
days we perform a thoracic computed to-
mographic scan.
A. Sortini, PhD
D. Sortini, MD
G. Carrella, MD
Department of Surgical, Anaesthesiological,
and Radiological Sciences
Section of Clinica Chirurgica
University of Ferrara
Ferrara, Italy
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Reply to the Editor:
My coauthors and I greatly appreciate Sor-
tini and colleagues’ comments, and we
agree with their premise that prompt resec-
tion of suspicious solitary pulmonary nod-
ules is the standard of care. However, this
is a separate issue from the central conclu-
sion of our report that there remains no
good evidence to indicate that watchful
waiting for selected patients worsens prog-
nosis. This question is unlikely to be an-
swered without a prospective trial, and we
are therefore left with reasoned discussion
of the evidence available.
Sortini and colleagues first take issue
with our suggestion that tumor biology,
and not just duration of tumor growth, may
be an important factor in the observation
that larger tumors are associated with a
worse prognosis. Our intent was to point
out that the data on tumor size and prog-
nosis provide only circumstantial evidence
for the importance of time and cannot be
interpreted as proof that watchful waiting is
necessarily bad. Other factors are also at
play, among which tumor biology, inde-
pendent of time, must be a consideration.
When confronted with a nodule of low
suspicion, we are then left with the ques-
tion of how important time is. This leads to
their second concern, that our choice of 90
days as a cutoff was inappropriate. They
suggest that comparison to a group of pa-
tients who had surgery within 10 to 15 days
would be more meaningful. This window is
as arbitrary as any other, and 90 days was
chosen for the variety of practical reasons
cited in our report. Unfortunately, we are
often confronted with circumstances be-
yond our control (such as delays in referral
to a specialist, comorbidities that require
evaluation and management, resource lim-
itations that delay scheduling of necessary
preoperative testing, and patient prefer-
ences) that limit our ability to bring pa-
tients to surgery expeditiously. Further-
more, we attempted to start the clock
ticking with the very first chest radiograph
that showed a nodule, as opposed to the
date of the chest computed tomographic
scan or the visit to the specialist. Thus a
15-day cutoff would be bound to produce a
cohort of patients that not only would be
small relative to the entire group but might
also be preselected for few comorbidities
and good performance status, factors that
are known to favorably affect prognosis.
Interestingly, Sortini and colleagues con-
clude by agreeing that short-term watchful
waiting is appropriate in selected circum-
stances. Thus the optimal duration of this
period remains the only open question.
They have chosen 20 days, an aggressive
approach that seems of questionable val-
ue.1 As mentioned in both our report and
Dr Ginsberg’s accompanying commen-
tary,2 new computed tomography algo-
rithms that enable volumetric modeling
may permit accurate assessments of dou-
bling times during relatively short periods
(although 20 days seems ambitious).1 The
potential for this technology is exciting, but
it is not yet either mature or widely avail-
able, and its value has not been demon-
strated.
We hope that one day we will be able to
tell with a high degree of certainty whether
any given lung nodule is benign or malig-
nant, and do so at reasonable cost with no
morbidity. Until then, we must deal with
the question of how much economic cost
and potential morbidity are justified by the
time benefit to those patients whose nod-
ules are malignant. Unfortunately, we have
so far been unable to quantify that benefit.
Mark I. Block, MD
Division of Cardiothoracic Surgery
Medical University of South Carolina
96 Jonathan Lucas St, 409 CSB
Charleston, SC 29425
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Malignant status at surgical margin
of limited-resected non–small cell
lung cancer: A crucial finding for
predicting local relapse
To the Editor:
In a recent issue, Higashiyama and col-
leagues1 reported on the malignant status
of the surgical margin of limited-resected
non–small cell lung cancer (NSCLC). They
concluded that the cytologically negative
results of examination of the surgical mar-
gin by the technique of intraoperative la-
vage in limited surgery for lung cancer may
be predict lack of local recurrence in the
surgical margin. The results in Higash-
iyama and colleagues’ study1 are similar to
those of my own investigation.2 As such, I
believe Higashiyama and colleagues’ tech-
nique is also useful to find out whether
NSCLC has been resected completely.
Although no recurrence on the malig-
nant negative surgical margin was found in
Higashiyama and colleagues’ study,1 I
have a criticism of their technique in cor-
recting cells on the surgical margin. It is
not rare that malignant cells exist on the
pleura in the naked situation3 and after
needle aspiration cytologic examination.4
Their complicated technique was lavage
cytologic examination without flooding the
pleura. If the pleura is flooded for even a
short while, malignant cells on the pleura
contaminate it. However, it is difficult to
avoid flooding the pleura with saline solu-
tion in a cup. Further, the spun cells degen-
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